GL701 dehydroepiandrosterone (DHEA): Update

A second study, begun in March 1996, involves 300 patients enrolled for 12 months and is intended to show whether the compound will improve symptoms and clinical outcome. A joint investment with the government of Taiwan, Genelabs Biotechnology Ltd. will conduct a third Phase III trial starting this quarter in 120 patients treated for 24 weeks. ...